(PM-28) The role of sex hormone binding globulin in hormonal clusters and Hypogonadal symptoms among men with severe sexual dysfunction requiring surgical treatment

Abstract Introduction Sex Hormone Binding Globulin (SHBG), measured in nmol/L, regulates testosterone availability to tissues. Its influence on clinical symptoms and hormonal clustering in men remains underexplored. We investigated SHBG levels across hormonal profiles in men with severe sexual dysfunction requiring surgery. Methods Retrospective cohort of 96 adult men from a tertiary center with erectile dysfunction (ED), Peyronie’s disease (PD), or both. Inclusion required a complete hormonal panel (Total Testosterone [TT; ng/dL], calculated free testosterone [cFT; pmol/mL], SHBG, LH [IU/L], FSH, estradiol) and a standardized consultation performed by a trained Urologist. cFT was calculated from TT and SHBG, both measured by chemo immunoassay. Patients were classified into five hormonal clusters (A–E as shown in table 1) based on TT, cFT, and LH. Clinical variables included age, BMI, comorbidities, and hypogonadism symptoms (≥3 considered relevant). SHBG differences across clusters and variable correlations with symptoms were analyzed. Results Median age was 67.5 ± 10 years; BMI 28.3 ± 5.7 kg/m2 (34% obese). ED was present in 43.7%, PD in 17.7%, and both in 35.4%. SHBG ranged from 6–110.5 nmol/L (median 39.9 ± 23.7). Group A (n = 23): 39.1% had ≥3 symptoms; B (n = 27): 37%; C (n = 19): 21%; D (n = 2): 0%; E (n = 25): 12%. SHBG differed significantly between A vs B (median 26.9 ± 9.3 vs 50.3 ± 28.1; p = 0.00004), A vs E (median 26.9 ± 9.3 vs 40 ± 23.2; p = 0.012), and B vs D (median 50.3 ± 28.1 vs 19.2 ± 1.2; p = 0.039). No variable strongly predicted ≥3 symptoms. Conclusion SHBG levels vary across hormonal profiles and impact underlying endocrine dynamics even when TT or cFT appear normal. These findings reinforce the importance of SHBG in phenotyping androgenic status and optimizing evaluation of men with complex sexual dysfunction. Financing No conflict.

Authors

Institutions

Publication Details

Journal
The Journal of Sexual Medicine
Published
2026-02-01
DOI
https://doi.org/10.1093/jsxmed/qdag002.065
Primary Topic
Hormonal and reproductive studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

(PM-28) The role of sex hormone binding globulin in hormonal clusters and Hypogonadal symptoms among men with severe sexual dysfunction requiring surgical treatment

Jorge Hallak, Lucas Vasconcelos Sanvido, Eduardo Zinoni Silva Pato, José de Bessa et al.
The Journal of Sexual Medicine
Hormonal and reproductive studies
article

(PM-28) The role of sex hormone binding globulin in hormonal clusters and Hypogonadal symptoms among men with severe sexual dysfunction requiring surgical treatment

Jorge Hallak, Lucas Vasconcelos Sanvido, Eduardo Zinoni Silva Pato, José de Bessa, W C Nahas, C A Rossetti, M Horta, J M da Cruz Sá, B C G Nascimento, V Fernandes Severino
article en

Abstract

Abstract Introduction Sex Hormone Binding Globulin (SHBG), measured in nmol/L, regulates testosterone availability to tissues. Its influence on clinical symptoms and hormonal clustering in men remains underexplored. We investigated SHBG levels across hormonal profiles in men with severe sexual dysfunction requiring surgery. Methods Retrospective cohort of 96 adult men from a tertiary center with erectile dysfunction (ED), Peyronie’s disease (PD), or both. Inclusion required a complete hormonal panel (Total Testosterone [TT; ng/dL], calculated free testosterone [cFT; pmol/mL], SHBG, LH [IU/L], FSH, estradiol) and a standardized consultation performed by a trained Urologist. cFT was calculated from TT and SHBG, both measured by chemo immunoassay. Patients were classified into five hormonal clusters (A–E as shown in table 1) based on TT, cFT, and LH. Clinical variables included age, BMI, comorbidities, and hypogonadism symptoms (≥3 considered relevant). SHBG differences across clusters and variable correlations with symptoms were analyzed. Results Median age was 67.5 ± 10 years; BMI 28.3 ± 5.7 kg/m2 (34% obese). ED was present in 43.7%, PD in 17.7%, and both in 35.4%. SHBG ranged from 6–110.5 nmol/L (median 39.9 ± 23.7). Group A (n = 23): 39.1% had ≥3 symptoms; B (n = 27): 37%; C (n = 19): 21%; D (n = 2): 0%; E (n = 25): 12%. SHBG differed significantly between A vs B (median 26.9 ± 9.3 vs 50.3 ± 28.1; p = 0.00004), A vs E (median 26.9 ± 9.3 vs 40 ± 23.2; p = 0.012), and B vs D (median 50.3 ± 28.1 vs 19.2 ± 1.2; p = 0.039). No variable strongly predicted ≥3 symptoms. Conclusion SHBG levels vary across hormonal profiles and impact underlying endocrine dynamics even when TT or cFT appear normal. These findings reinforce the importance of SHBG in phenotyping androgenic status and optimizing evaluation of men with complex sexual dysfunction. Financing No conflict.

The Journal of Sexual MedicineVol. 23(Supplement_1)
Universidade de São Paulo (BR), Universidade Estadual de Feira de Santana (BR), Hospital Israelita Albert Einstein (BR), Hospital Universitário da Universidade de São Paulo (BR)
Openalex Percentile: Top 69%
Hormonal and reproductive studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.